Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Sharpless Steps Down as NCI Director
April 4th 2022

Sharpless Steps Down as NCI Director

Mary Caffrey
Norman E. “Ned” Sharpless, MD, is departing shortly after the launch of Cancer Moonshot 2.0, an initiative that aims to reduce the cancer death rate by at least half over the next 25 years while improving the experience for all those affected by cancer.
Addressing Cancer Health Disparities in a Multilateral Collaboration in an Independent Community Cancer Clinic: Translating Words Into Action
March 15th 2022

Addressing Cancer Health Disparities in a Multilateral Collaboration in an Independent Community Cancer Clinic: Translating Words Into Action

Kashyap Patel, MD Hirangi Mukhi, BS Anjana Patel, BSc Niyati Nathwani, MD Dhwani Mehta, MS Jennifer Sherak, MBA Natasha Clinton, MSN, APRN, AOCNP Holly Pisarik, JD Benjamin Brown, BS Sara Rogers, PharmD Mary Kruczynski Nicolas Ferreyros, BA Ted Okon, MBA
No One Left Behind, a program to provide financial assistance and access to cancer care at Carolina Blood and Cancer Care Associates in South Carolina, will be discussed during a session of the Community Oncology Alliance 2022 Community Oncology Conference.
Patel et al, Appendix B
March 15th 2022

Patel et al, Appendix B

COA 2022 Preview: Leaders Excited About Seeing Colleagues in Person
March 14th 2022

COA 2022 Preview: Leaders Excited About Seeing Colleagues in Person

Mary Caffrey
The first in-person Community Oncology Alliance (COA) meeting in 2 years will feature sessions on practice management, health disparities, and more. A virtual option is available.
Site Logo
March 9th 2022

Oncology Alternative Payment Models: Lessons From Commercial Insurance

Elizabeth Shaughnessy, MA David C. Johnson, MD, MPH Aaron J. Lyss, MBA Ravi B. Parikh, MD, MPP Steven R. Peskin, MD, MBA, MACP Blase N. Polite, MD, MPP Julie A. Royalty Bhuvana Sagar, MD, MBA Erin Smith, JD Lindee Goh, PhD
Developing alternative payment models for commercial populations in specialties such as oncology is rife with practical challenges. Leading payers and practices share lessons to date.
Purva Rawal, PhD
February 21st 2022

CMS Official Cites OCM as Example of Biosimilar Success

Mary Caffrey
Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.
Joseph Alvarnas, MD
February 16th 2022

From the Editor-in-Chief: From the Earth to the Moon (and Back)

Joseph Alvarnas, MD
The president’s aim is a 50% reduction in age-adjusted cancer deaths by 2047. This goal seems audacious, but it is likely achievable.
DNA.
February 15th 2022

Tumor Mutational Burden May Help Predict Immunotherapy Response in Metastatic NSCLC

Matthew Gavidia
Response to immunotherapy and survival outcomes were found to be significantly associated with tumor mutational burden in patients with stage IV non-small cell lung cancer.
Emory’s Winship Joins AccessHope as Collaboration Partner
February 14th 2022

Emory’s Winship Joins AccessHope as Collaboration Partner

Mary Caffrey
AccessHope is a program that allows patients and community oncologists to tap into the expertise of City of Hope, often through electronic sharing of records so the patient does not have to travel.
SAP badge AJMC
February 14th 2022

From Our Partners: Schleicher, Dickson Take New Roles at Tennessee Oncology

Hayden E. Klein Mary Caffrey
The changes come as Tennessee Oncology must now plan for a gap between the Oncology Care Model and a future alternative payment model from CMS.
What We're Reading
February 2nd 2022

What We’re Reading: Cancer Moonshot Returns; New Omicron Subvariant; Drug Overdose Suicide Rates

AJMC Staff
President Biden announced he would bring back the Cancer Moonshot initiative that launched in the Obama administration; the World Health Organization said the Omicron subvariant, BA.2, appears to have the same severity as the original Omicron variant; cases of suicide by drug overdose increased in young people, older adults, and non-Hispanic Black women.
COA Survey: Practices Find OCM a Success; Some Added Services May Be at Risk
January 31st 2022

COA Survey: Practices Find OCM a Success; Some Added Services May Be at Risk

Mary Caffrey
The Oncology Care Model (OCM) is set to expire June 30, 2022. With no successor on the horizon, respondents to a recent survey by the Community Oncology Alliance (COA) say features such as dedicated navigators and weekend appointments could be reduced or lost if revenues that supported them are eliminated.
Site Logo
January 11th 2022

Management of TRK Fusion Cancer: Evaluating Targeted Therapies - Participating Faculty

Site Logo
January 11th 2022

Diagnosis and Management of TRK Fusion Cancer

Shivaani Kummar, MD, FACP Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Josh J. Carlson, PhD, MPH Sean D. Sullivan, PhD, MSc, RPh Ulrik Lassen, MD, PhD Noah Federman, MD
Site Logo
January 11th 2022

Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

Josh J. Carlson, PhD, MPH Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Noah Federman, MD Ulrik Lassen, MD, PhD Shivaani Kummar, MD, FACP Sean D. Sullivan, PhD, MSc, RPh
Stephen Schleicher, MD, MBA
January 3rd 2022

Tennessee Oncology Names Dr Stephen Schleicher CMO, Dr Natalie Dickson CSO

Hayden E. Klein
Tennessee Oncology appointed Stephen Schleicher, MD, MBA, as Chief Medical Officer (CMO), with president Natalie Dickson, MD, being promoted from CMO to Chief Strategy Officer (CSO).
Burt Zweigenhaft, PhD, DLitt, Upstream Partners
December 20th 2021

CONFERENCE COVERAGE: Asembia 2021

Matthew Gavidia
Coverage from the Asembia 2021 Specialty Pharmacy Summit in Las Vegas.
PCOC Spotlight: There’s Been a Lot of Good for Patients With the OCM, Says US Oncology’s Neubauer
December 20th 2021

PCOC Spotlight: There’s Been a Lot of Good for Patients With the OCM, Says US Oncology’s Neubauer

Laura Joszt, MA
Marcus Neubauer, MD, chief medical officer, The US Oncology Network. He is an expert in precision medicine, value-based care, and clinical pathways.
PCOC Spotlight: How Community Oncology Is a Low-Cost, High-Quality Provider
December 20th 2021

PCOC Spotlight: How Community Oncology Is a Low-Cost, High-Quality Provider

Laura Joszt, MA
Jeffrey Patton, MD, is the CEO of OneOncology, a national partnership of independent community oncologists based in Nashville, Tennessee. He is also executive chairman of the board, Tennessee Oncology, and a member of the board, Community Oncology Alliance.
In Oncology, Navigating PBMs Starts With Knowing What’s in the Contract
December 20th 2021

In Oncology, Navigating PBMs Starts With Knowing What’s in the Contract

Mary Caffrey
Vertical integration of payers and pharmacy benefit managers (PBMs) took flight with the mergers of Aetna and CVS Health and of Cigna and ExpressScripts. Panelists at Patient-Centered Oncology Care® said the shift has filtered down to affect access at the practice level.
Panel Discusses the Ongoing Evolution of Remote Patient Care
December 19th 2021

Panel Discusses the Ongoing Evolution of Remote Patient Care

Maggie L. Shaw
The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.
PCOC SPOTLIGHT: In Taking on Disparities, What Is Actionable? What Can We Share With the Nation?
December 19th 2021

PCOC SPOTLIGHT: In Taking on Disparities, What Is Actionable? What Can We Share With the Nation?

Laura Joszt, MA
Karen Winkfield, MD, PhD, is the executive director of the Meharry-Vanderbilt Alliance, a strategic partnership between Meharry Medical College and Vanderbilt College of Medicine, Nashville, Tennessee. She is also Ingram Professor of Cancer Research and professor of radiation oncology, Vanderbilt-Ingram Cancer Center.
PCOC SPOTLIGHT: Patel Says Let the OCM Continue for Now
December 19th 2021

PCOC SPOTLIGHT: Patel Says Let the OCM Continue for Now

Laura Joszt, MA
The Oncology Care Model (OCM) is scheduled to end in just a few months, but with no new model in place to succeed it and practices still struggling during the pandemic, CMS should allow OCM to continue, said Kashyap Patel, MD, a co-chair of Patient-Centered Oncology Care® and the current president of the Community Oncology Alliance. He is CEO of Carolina Blood and Cancer Care Associates.
PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology
December 19th 2021

PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology

Allison Inserro
Joseph Alvarnas, MD, a co-chair of Patient-Centered Oncology Care® (PCOC), discussed the unique nature of PCOC and what it offers for providers, payers, policy leaders, and technology experts who take part. Alvarnas is vice president, Government Affairs; senior medical director, employer strategy, and clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope.
Surveys Probe Biosimilars in Oncology
December 13th 2021

Surveys Probe Biosimilars in Oncology

Tony Hagen
Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.
Site Logo
December 9th 2021

Mental Health Distress Impacting Cancer Patients, Says New Cardinal Health Survey of Oncologists

More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.
Kathleen Maignan, MSN, NP
December 8th 2021

Flatiron Health Leverages Expertise With Real-World Data to Examine Cancer Care Disparities

Mary Caffrey
Physician and patient.
November 23rd 2021

Achieving Equitable Breast Cancer Care: Clinical Trials, Mental Health, and Digital Therapeutics

Matthew Gavidia
Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.
Karen van Caulil, PhD
November 22nd 2021

Dr Karen van Caulil: End of Oncology Care Model Could Leave Gap in Comprehensive Care

Hayden E. Klein
Karen L. van Caulil, PhD, president and CEO of Florida Alliance for Healthcare Value, discusses the potential gap in care that may occur with the end of the Oncology Care Model.
With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?
November 22nd 2021

With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?

Gianna Melillo
The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.
<1
...
131415161718192021
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo